BOTOX for masseter muscle prominence

Phase 3, randomised, double-blind trial of botulinum toxin (3 arms), sponsored by AbbVie Inc. Primary endpoints: Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale as assessed by the Investigator at Day 90 and Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale - Participant as assessed by the Participant at Day 90. Started Oct 2023; status: completed.